Lamivudine NEW
| Price | $79 | $189 |
| Package | 100mg | 500mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-20 |
Product Details
| Product Name: Lamivudine | CAS No.: 134678-17-4 |
| Purity: 98.71% | Supply Ability: 10g |
| Release date: 2026/04/20 |
Product Introduction
Bioactivity
| Name | Lamivudine |
| Description | Lamivudine (BCH-189) is a reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. |
| In vivo | Lamivudine exhibits selective inhibitory activity against deoxycytidine kinase, an unusual substrate for the non-natural L-isomer of dNTPs preferred by HBV polymerase. The anti-HBV activity of PCV is attributed to the broad substrate specificity of deoxycytidine kinase and an unusual substrate preference of HBV polymerase for the non-natural L-conformation of dNTPs. The anti-HBV efficacy of PCV appears to rely on multiple factors, including optimal phosphorylation (sufficient for antiviral activity but not cytotoxicity), the extended intracellular half-life of PCV-TP, and the ability of PCV-TP to inhibit the initiation of HBV RT as well as its RT and DNA polymerase activities. Combined use of Lamivudine and Cidofovir synergistically inhibits replication of duck hepatitis B virus and is more effective in reducing the persistent covalently closed circular (CCC) DNA form of DHBV than when used separately. In PBMCs, Lamivudine inhibits HIV-1 p24 antigen production with ED50s ranging from 0.07 μM to 0.2 μM. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (21.81 mM), Sonication is recommended. DMSO : 240 mg/mL (1046.85 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : 42 mg/mL (183.2 mM), Sonication is recommended. |
| Keywords | susceptible | ReverseTranscriptase | Reverse Transcriptase | orally active | Lamivudine | Inhibitor | inhibit | Human immunodeficiency virus | HIVProtease | HIV Protease | HIV neurodegeneration | HIV | Hepatitis B virus | HBV | CNS penetration,brain region | BCH189 | BCH 189 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Dolutegravir intermediate-1 | Dimethyl fumarate | Valproic Acid | (-)-Epigallocatechin Gallate | Thiamine hydrochloride | Decanedioic acid | Dextran sulfate sodium salt (MW 5000) | Nicotinamide | Tenofovir |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bitter Compound library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:1391052-30-4
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-19 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-07-17 | ||
| $412.00 |
VIP6Y
|
Baoji Guokang Healthchem Co., Ltd.
|
2026-07-15 | |
| $185.00 |
VIP6Y
|
Sinoway Industrial co., ltd.
|
2026-07-02 | |
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 | ||
|
VIP1Y
|
Hefei Lbao Physical & Chemical Science Co.,Ltd
|
2026-05-18 | ||
| $79.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-20 | |
| $10.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2025-11-18 | |
| $150.00 |
Hebei Zhuanglai Chemical Trading Co Ltd
|
2025-05-23 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY